3-glyoxylamideindoles for treating cancer

A method of treating a subject with cancer, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is substituted or unsubstituted and is optionally fused to an aryl group;
• Z1 and Z2 are independently ═O, ═S, ═N—OR9 or ═NR9;
• R4 is —H, a substituted alkyl group or an unsubstituted alkyl group;
• R9 is —H or a substituted or unsubstituted alkyl group;
• each R15 is independently —Br, —Cl, —F, —R18, —OR18, —CN, —COOR18, —N(R18)2, —CON(R18)2, —NR18COR19, —NHCONH2 and —SO2N(R18)2;
• n is an integer from 1-4;
• R16 and R17 are independently —H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an unsubstituted carbocyclic aryl group, a substituted carbocyclic aryl group;
• a substituted or unsubstituted imidazolyl, a substituted or unsubstituted isoimidazolyl, a substituted or unsubstituted thienyl, a substituted or unsubstituted furanyl, a substituted or unsubstituted pyridyl, a substituted or unsubstituted pyranyl, a substituted or unsubstituted pyrrolyl, a substituted or unsubstituted pyrazinyl, a substituted or unsubstituted isothiazolyl, a substituted or unsubstituted oxazolyl, a substituted or unsubstituted isoxazolyl, a substituted or unsubstituted 1,2,3-triazolyl, a substituted or unsubstituted 1,2,4-triazolyl, a substituted or unsubstituted tetrazolyl, a substituted or unsubstituted benzothienyl, a substituted or unsubstituted benzofuranyl, a substituted or unsubstituted indolyl, a substituted or unsubstituted quinolinyl, a substituted or unsubstituted benzothiazolyl, a substituted or unsubstituted benzoisothiazolyl, a substituted or unsubstituted benzoxazolyl, a substituted or unsubstituted benzoisoxazolyl, a substituted or unsubstituted benzoimidazolyl, a substituted or unsubstituted quinolinyl, a substituted or unsubstituted isoquinolinyl or a substituted or unsubstituted isoindolyl;
• or —NR16R17, taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group;
• and
• R18 and R19 are independently —H, alkyl or substituted alkyl, wherein the cancer is human breast cancer, human myeloid leukemia, human uterine sarcoma, human prostate cancer, human leukemia, or a multidrug resistant strain thereof.

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is substituted or unsubstituted and is optionally fused to an aryl group;
• Z1 and Z2 are independently ═O, ═S, ═N—OR9 or ═NR9;
• R4 is —H, a substituted alkyl group or an unsubstituted alkyl group;
• R9 is —H or a substituted or unsubstituted alkyl group;
• each R15 is independently —Br, —Cl, —F, —R18, —OR18, —CN, —COOR18, —N(R18)2, —CON(R18)2, —NR18COR19, —NHCONH2 or —SO2 N(R18)2;
• n is an integer from 1-4;
• R16 and R17 are independently —H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an unsubstituted carbocyclic aryl group, a substituted carbocyclic aryl group;
• a substituted or unsubstituted imidazolyl, a substituted or unsubstituted isoimidazolyl, a substituted or unsubstituted thienyl, a substituted or unsubstituted furanyl, a substituted or unsubstituted pyridyl, a substituted or unsubstituted pyranyl, a substituted or unsubstituted pyrrolyl, a substituted or unsubstituted pyrazinyl, a substituted or unsubstituted isothiazolyl, a substituted or unsubstituted oxazolyl, a substituted or unsubstituted isoxazolyl, a substituted or unsubstituted 1,2,3-triazolyl, a substituted or unsubstituted 1,2,4-triazolyl, a substituted or unsubstituted tetrazolyl, a substituted or unsubstituted benzothienyl, a substituted or unsubstituted benzofuranyl, a substituted or unsubstituted indolyl, a substituted or unsubstituted quinolinyl, a substituted or unsubstituted benzothiazolyl, a substituted or unsubstituted benzoisothiazolyl, a substituted or unsubstituted benzoxazolyl, a substituted or unsubstituted benzoisoxazolyl, a substituted or unsubstituted benzoimidazolyl, a substituted or unsubstituted quinolinyl, a substituted or unsubstituted isoquinolinyl or a substituted or unsubstituted isoindolyl;
• or —NR16R17, taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group;
• and
• R18 and R19 are independently —H, alkyl or substituted alkyl.